ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026
Globe Newswire•23/10/2026•03:15 ET
0
Key Highlights
- ➤Rinzimetostat maintained potency against an EZH2 resistance mutation emerging with mevrometostat.
- ➤No hematologic tumorigenesis appeared in rinzimetostat rat toxicology, unlike tazemetostat findings.
- ➤Rinzimetostat synergized with androgen receptor inhibition in preclinical prostate cancer studies.
- ➤mCRPC patient samples showed increased AR signaling after one rinzimetostat treatment cycle.
- ➤ORIC is evaluating rinzimetostat across prostate cancer, including the ongoing Himalayas-1 Phase 3 trial.
Expert Statements
Lori Friedman, Chief Scientific Officer of ORIC Pharmaceuticals
“These results strengthen the rationale for combining PRC2 inhibition with androgen receptor targeted therapies across castration-sensitive and castration-resistant prostate cancer by limiting tumor adaptability and enhancing sensitivity to AR inhibition.”
Lori Friedman, Chief Scientific Officer of ORIC Pharmaceuticals
“Verification of our preclinical results in patient samples, together with the potential advantages of targeting PRC2 via EED, reinforce our confidence in rinzimetostat’s potential best-in-class profile and support its evaluation across the prostate cancer disease spectrum, including in our ongoing Himalayas-1 Phase 3 trial.”
Preclinical data highlight potential advantages of targeting PRC2 via EED over EZH2, including the emergence of resistance mutations to EZH2 inhibitors like mevrometostat and against which the EED inhibitor rinzimetostat maintained effectiveness
Preclinical results, supported by translational data in mCRPC patient samples, show rinzimetostat reinforces a luminal, AR-dependent state, restricts lineage plasticity and enhances sensitivity to AR inhibition
Get started
Create a free account to read the full story.